Matches in SemOpenAlex for { <https://semopenalex.org/work/W121169304> ?p ?o ?g. }
Showing items 1 to 95 of
95
with 100 items per page.
- W121169304 endingPage "90" @default.
- W121169304 startingPage "679" @default.
- W121169304 abstract "Castleman disease is a rare idiopathic non-neoplastic lymphoproliferative disorder with 2 clinical (unicentric and multicentric) and 3 histomorphological (hyaline-vascular, plasma-cell and mixed) forms identified. The case report given here describes the 3-year experience with therapy in a patient, male born 1961, diagnosed with multicentric plasma-cell Castleman disease (HIV and HHV-8 negative) with the finding of generalized lymphadenopathy and splenomegaly. During first line treatment (R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, 3 cycles in total, 12/2008-2/2009) the development of bilateral upper and lower limb edemas with clinical manifestation of vasculitis occurred and a restaging computed tomography (CT) examination revealed a stable finding of the lymphadenomegaly. Greater success was achieved with thalidomide regimen (CTD: cyclophosphamide, thalidomide, dexamethasone, 10 cycles, 3/2009-1/2010) leading to reduction in the size of the hypervascularized lymph nodes (almost by 50%) as well as their radiopharmaceutical (fluorodeoxyglucose) uptake as seen on a combined positron emission tomography and computed tomography (PET/CT) scan imaging. Thalidomide was given daily at doses between 100 and 200 mg. We returned to the CTD regimen again in April 2010 after a short period of monoclonal antibody tocilizumab treatment (400 mg intravenous in 2-week intervals with 50% dose reduction due to a limited supply of the drug, 5 doses in total) during which edemas reoccurred with a CT scan finding of stable lymphadenomegaly. However, the renewed regimen with thalidomide was stopped after 2.5 cycles due to adverse effects of thalidomide (neuropathy) and corticoids (Cushing syndrome). In September 2010, after enrollment in the Celgenes Compassionate Use Program we were able to start treating the patient with the derivative of thalidomide, lenalidomide, at a dosage of 25 mg on days 1-21 in a 28-day cycle, 15 cycles in total (10/2010-12/2011). The monotherapy with lenalidomide was very well tolerated by the patient without any effects of myelotoxicity, thromboembolism or relapses of edemas and vasculitis, additionally now with apparent improvement of fatic disorder and the patients motor abilities. Thus, lenalidomide represents an attractive alternative agent for patients with Castleman disease after rituximab and cytostatics failures. It has a favourable safety profile and could be therefore considered for administering in first line treatment." @default.
- W121169304 created "2016-06-24" @default.
- W121169304 creator A5014056436 @default.
- W121169304 creator A5015205483 @default.
- W121169304 creator A5021539818 @default.
- W121169304 creator A5027611733 @default.
- W121169304 creator A5033638555 @default.
- W121169304 creator A5038774527 @default.
- W121169304 creator A5043155534 @default.
- W121169304 creator A5054654885 @default.
- W121169304 creator A5059792688 @default.
- W121169304 creator A5062071138 @default.
- W121169304 creator A5064598999 @default.
- W121169304 creator A5089870813 @default.
- W121169304 date "2012-09-01" @default.
- W121169304 modified "2023-09-23" @default.
- W121169304 title "[Our experience in treatment of multicentric plasma-cell Castleman disease associated with vasculitis manifestations - case report and literature review]." @default.
- W121169304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23094815" @default.
- W121169304 hasPublicationYear "2012" @default.
- W121169304 type Work @default.
- W121169304 sameAs 121169304 @default.
- W121169304 citedByCount "1" @default.
- W121169304 countsByYear W1211693042018 @default.
- W121169304 crossrefType "journal-article" @default.
- W121169304 hasAuthorship W121169304A5014056436 @default.
- W121169304 hasAuthorship W121169304A5015205483 @default.
- W121169304 hasAuthorship W121169304A5021539818 @default.
- W121169304 hasAuthorship W121169304A5027611733 @default.
- W121169304 hasAuthorship W121169304A5033638555 @default.
- W121169304 hasAuthorship W121169304A5038774527 @default.
- W121169304 hasAuthorship W121169304A5043155534 @default.
- W121169304 hasAuthorship W121169304A5054654885 @default.
- W121169304 hasAuthorship W121169304A5059792688 @default.
- W121169304 hasAuthorship W121169304A5062071138 @default.
- W121169304 hasAuthorship W121169304A5064598999 @default.
- W121169304 hasAuthorship W121169304A5089870813 @default.
- W121169304 hasConcept C126322002 @default.
- W121169304 hasConcept C126838900 @default.
- W121169304 hasConcept C142724271 @default.
- W121169304 hasConcept C2776364478 @default.
- W121169304 hasConcept C2776694085 @default.
- W121169304 hasConcept C2776755627 @default.
- W121169304 hasConcept C2777178219 @default.
- W121169304 hasConcept C2778720950 @default.
- W121169304 hasConcept C2778964538 @default.
- W121169304 hasConcept C2779134260 @default.
- W121169304 hasConcept C2779338263 @default.
- W121169304 hasConcept C2779429289 @default.
- W121169304 hasConcept C2779609412 @default.
- W121169304 hasConcept C2780151071 @default.
- W121169304 hasConcept C2780653079 @default.
- W121169304 hasConcept C2781413609 @default.
- W121169304 hasConcept C2909638373 @default.
- W121169304 hasConcept C71924100 @default.
- W121169304 hasConcept C90924648 @default.
- W121169304 hasConceptScore W121169304C126322002 @default.
- W121169304 hasConceptScore W121169304C126838900 @default.
- W121169304 hasConceptScore W121169304C142724271 @default.
- W121169304 hasConceptScore W121169304C2776364478 @default.
- W121169304 hasConceptScore W121169304C2776694085 @default.
- W121169304 hasConceptScore W121169304C2776755627 @default.
- W121169304 hasConceptScore W121169304C2777178219 @default.
- W121169304 hasConceptScore W121169304C2778720950 @default.
- W121169304 hasConceptScore W121169304C2778964538 @default.
- W121169304 hasConceptScore W121169304C2779134260 @default.
- W121169304 hasConceptScore W121169304C2779338263 @default.
- W121169304 hasConceptScore W121169304C2779429289 @default.
- W121169304 hasConceptScore W121169304C2779609412 @default.
- W121169304 hasConceptScore W121169304C2780151071 @default.
- W121169304 hasConceptScore W121169304C2780653079 @default.
- W121169304 hasConceptScore W121169304C2781413609 @default.
- W121169304 hasConceptScore W121169304C2909638373 @default.
- W121169304 hasConceptScore W121169304C71924100 @default.
- W121169304 hasConceptScore W121169304C90924648 @default.
- W121169304 hasIssue "9" @default.
- W121169304 hasLocation W1211693041 @default.
- W121169304 hasOpenAccess W121169304 @default.
- W121169304 hasPrimaryLocation W1211693041 @default.
- W121169304 hasRelatedWork W2025506316 @default.
- W121169304 hasRelatedWork W2165800290 @default.
- W121169304 hasRelatedWork W2339363185 @default.
- W121169304 hasRelatedWork W2460189784 @default.
- W121169304 hasRelatedWork W2950246407 @default.
- W121169304 hasRelatedWork W3008664103 @default.
- W121169304 hasRelatedWork W3026939985 @default.
- W121169304 hasRelatedWork W3089840555 @default.
- W121169304 hasRelatedWork W3212185513 @default.
- W121169304 hasRelatedWork W393684935 @default.
- W121169304 hasVolume "58" @default.
- W121169304 isParatext "false" @default.
- W121169304 isRetracted "false" @default.
- W121169304 magId "121169304" @default.
- W121169304 workType "article" @default.